Invasion factors uPA and PAI-1 in node-negative breast cancer: Transfer of laboratory data into clinical practice as exemplified by the ongoing NNBC 3-Europe trial;Invasionsfaktoren uPA/PAI-1 im tumorgewebe bei patientinnen mit primärem mammakarzinom: Von forschungsergebnissen zur klinischen anwendung am beispiel der NNBC 3-Europe-studie

Geburtshilfe und Frauenheilkunde

Volumn 67, Issue 10, 2007, Pages 1144-1152

  Vetter, Martina ^a   Kantelhardt, E J ^b   Annecke, K ^b   Dittmer, J ^b   Paepke, D ^b   Prechtl, A ^b   Schmitt, M ^b   Janicke F ^b   Minckwitz, G V ^b   Kiechle Bahat, M ^b   Thomssen, C ^b   Harbeck, N ^b  

^a MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

^b NONE

Author keywords

Biological prognostic factors; Breast cancer; Clinical trial NNBC 3 Europe; Predictive factors; Translational research; uPA PAI 1

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; UROKINASE;

ARTICLE; BREAST CANCER; CANCER RISK; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL RESEARCH; HISTOPATHOLOGY; HUMAN; PROGNOSIS;

EID: 36049019348     PISSN: 00165751     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-965742     Document Type: Article

References (63)

1. Longstaff C, Thelwell C. Understanding the enzymology of fibrinolysis and improving thrombolytic therapy. FEBS Lett 2005; 579: 3303-3309
2. Myohanen H, Vaheri A. Regulation and interactions in the activation of cell-associated plasminogen. Cell Mol Life Sci 2004; 61: 2840-2858
3. Collen D, Lijnen HR. Thrombolytic agents. Thromb Haemost 2005; 93: 627-630
4. Ellis V. Plasminogen activation at the cell surface. Curr Top Dev Biol 2003; 54: 263-312
5. Nielsen LS, Hansen JG, Skriver L, Wilson EL, Kaltoft K, Zeuthen J, Danø K. Purification of zymogen to plasminogen activator from human glioblastoma cells by affinity chromathography with monoclonal antibody. Biochemistry 1982; 21: 6410-6415
6. Hahn-Dantona E, Ramos-DeSimone N, Sipley J, Nagase H, French DL, Quigley JP. Activation of proMMP9 by plasmin/MMP-3 cascade in a tumor cell model: Regulation of tissue inhibitors of metalloproteinases. Ann NY Acad Sci 1999; 878: 372-387
7. Duffy MJ, Maguire TM, Hill A, McDermott E, O'Higgins. Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res 2000; 2: 252-257
8. Waltz DA, Chapman HA. Reversible cellular adhesion to vitronectin linked to urokinase receptor occupancy. J Biol Chem 1994; 269: 14746-14750
9. Loskutoff DJ, Curriden SA, Hu G et al. Regulation of cell adhesion by PAI-1. APMIS 1999; 107: 54-61
10. Binder BR, Mihaly J, Prager GW. uPAR - uPA - PAI-1 interactions and signaling: A vascular biologist's view. Throm Haemost 2007; 97: 336-342
11. Jo M, Thomas KS, Marozkina, Amin TJ, Silva CM, Parsons SJ et al. Dynamic assembly of the urokinase-type plasminogen activator signaling receptor complex determines the mitogenic activity of urokinase-type plasminogen activator. J Biol Chem 2005; 280: 17449-17457
12. Medcalf RL, Stasinopoulos SJ. The undecided serpin. The ins and outs of plasminogen activator inhibitor type-2. FEBS J 2005; 272: 4858-4867
13. Schmitt M, Lienert S, Prechtel D et al. The urokinase protease system as a target for breast cancer prognosis and therapy: Technical considerations. Journal of Clinical Ligand Assay 2002; 25: 43-52
14. Sweep CG, Geurts-Moespot J, Grebenschikov N et al. External quality assessment of trans-European multicentre antigen determination (Enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 Inhibitor (PAI-1) in human breast cancer tissue extracts. Br J Cancer 1998; 78: 1434-1441
15. Sweep FC, Fritsche HA, Gion M et al. Considerations on development, validation, application and quality control of immuno(metric) biomarker assays in clinical cancer research: an EORTC-NCI working group report. Int J Oncol 2003; 23: 1715-1726
16. Leissner P, Verjat T, Bachelot T et al. Prognostic significance of urokinase plasminogen activator and plasminogen activator inhibitor-1 mRNA expression in lymph node- and hormone receptor-positive breast cancer. BMC Cancer 2006; 6: 216
17. Spyratos F, Bouchet C, Tozlu S et al. Prognostic value of uPA, PAI-1 and PAI-2 mRNA expression in primary breast cancer. Anticancet Res 2002; 22: 2997-3003
18. Castello R, Estelles A, Vazquez C et al. Quantitative real-time reverse ttanscription-PCR assay for urokinase plasminogen activator, plasminogen activator inhibitor type 1, and tissue metalloproteinase inhibitor type 1 gene expressions in primary breast cancer. Clin Chem 2002; 48: 1288-1295
19. Pakneshan P, Tetu B, Rabbani SA. Demethylation of urokinase promoter as a prognostic marker in patients with breast carcinoma. Clin Cancer Res 2004; 10: 3035-3041
20. Pakneshan P, Szyf M, Rabbani SA. Hypomethylation of urokinase (uPA) promoter in breast and prostate cancer: prognostic and therapeutic implications. Curr Cancer Drug Targets 2005; 5: 471-488
21. Thomssen C, Jänicke F, Harbeck N. Clinical relevance of prognostic factors in axillary node-negative breast cancer. Onkologie 2003; 26: 438-445
22. Diel IJ, Neumaier M, Schuetz F. Bone marrow micrometastases and circulating tumor cells. Chapter 40. In: Harris JR et al. (eds). Diseases of the Breast. Philadelphia: Lippincott, 2004: 697-707
23. Chang JC, Hilsenbeck SG. Prognostic and predictive Markers. Chapter 40. In: Harris JR et al. (eds). Diseases of the Breast. Philadelphia: Lippincott, 2004: 675-696
24. Gandolfo GM, Conti L, Vercillo M. Fibrinolysis components as prognostic markers in breast cancer and colorectal carcinoma. Anticancer Res 1996; 16: 2155-2159
25. Andreasen PA, Kjoller L, Christensen L, Duffy MJ. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 1997; 72: 1-22
26. Astrup T, Permin D. Fibrinolysis in the animal organism. Nature 1947; 159: 681-682
27. Astedt B, Holmberg L. Immunological identity of urokinase and ovarian carcinomas plasminogen activator released in tissue culture. Nature 1976; 261: 595-597
28. Dano K, Andreasen PA, Grondahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators and cancer. Adv in Cancer Res 1985; 44: 139-266
29. Duffy MJ, O'Grady P, Devaney D, O'Siorain L, Fennelly JJ, Lijnen HJ. Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report. Cancer 1988; 62: 531-533
30. Jänicke F, Schmitt M, Ulm K, Gossner W, Graeff J. Urokinase-type plasminogen activator antigen and eatly relapse in breast cancer. Lancet 1989; 2: 1049
31. Duffy MJ, Reilly D, O'Sullivan, O'Higgins N, Fennelly JJ, Andreasen P. Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res 1990; 50: 6827-6829
32. Jänicke F, Schmitt M, Hafter R et al. Urokinase-type plasminogen activator (u-PA) antigen is a predictor of early relapse in breast cancer. Fibrinolysis 1990; 4: 69-78
33. Jänicke F, Schmitt M, Graeff H. Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Semin Thromb Hemost 1991; 17: 303-312
34. Jänicke F, Pache L, Schmitt M et al. Both the cytosols and detergent extracts of breast cancer tissue are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1. Cancer Res 1994; 54: 2527-2530
35. Harbeck N, Thomssen C, Berger U et al. Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-up both for primary breast cancer and following first relapse. Breast Cancer Res Treat 1999; 54: 147-157
36. Harbeck N, Kates RE, Schmitt M et al. Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and thetapy response in primary breast cancer. Clin Breast Cancer 2004; 5: 348-352
37. Harbeck N, Kates RE, Look MP et al. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424). Cancer Res 2002; 62: 4617-4622
38. Harbeck N, Kates RE, Schmitt M. Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination. J Clin Oncol 2002; 20: 1000-1007
39. Kim SJ, Shiba E, Kobayashi T et al. Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1 and tissue-type PA antigen levels in node-negative breast cancer: a prospective study on multicenter basis. Clin Cancer Res 1998; 4: 177-182
40. Foekens JA, Peters JA, Look MP et al. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res 2000; 60: 636-643
41. Zemzoum I, Kates RE, Ross JS et al. Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer. J Clin Oncol 2003; 21: 1022-1028
42. Urban P, Vuaroqueaux V, Labuhn M et al. Increased expression of urokinase-type plasminogen activator mRNA determines adverse prognosis in ErbB2-positive primary breast cancer. J Clin Oncol 2006; 24: 4245-4253
43. Hayes DF, Bast R, Desch CE et al. A tumor marker utility grading system (TMUGS): a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996; 88: 1456-1466
44. Jänicke F, Prechtl A, Thomssen C et al. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst 2001; 93: 913-920
45. Harbeck N, Meisner C, Prechtl A et al. Level-1 evidence for prognostic and predictive impact of uPA and PAI-1 in node-negative breast cancer provided by second scheduled analysis of multicenter Chemo-N0 therapy trial. Breast Cancer Res Treat 2001; 69: 213
46. Look MP, van Putten WLK, Duffy MJ et al. Pooled analysis of prognostic impact of utokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 2002; 94: 116-128
47. McGuire WL, Tandon AK, Alred DC, Chamness GC, Clark GM. Commentaries. How to use prognostic factors in axillary node-negative breast cancer patients. J Nat Cancer Inst 1990; 82: 1006-1015
48. Harbeck N, Kates RE, Look MP et al. Enhanced benefit from adjuvant systemic chemotherapy in breast cancer patients classified high-risk according to uPA and PAI-1. Cancer Res 2002; 62: 4617-4622
49. Harbeck N, Kates RE, Look MP, Foekens JA, on behalf of pooled analysis study of the EORTC receptor and biomarker group (RBG). Pooled analysis (n = 8, 377) evaluates predictive impact of uPA and PAI-1 for response to adjuvant therapy in breast cancer. J Clin Oncol 2004; 23: 85 (523)
50. Cufer T, Borstnar S, Vrhovec I. Prognostic and predictive value of the urokinase-type plasminogen activator (uPA) and its inhibitors PAI-1 and PAI-2 in operable breast cancer. Int J Biol Markers 2003; 18: 106-115
51. Pierga JY, Laine-Bidron C, Beuzeboc P et al. Plasminogen activator inhibitor-1 (PAI-1) is not related to response to neoadjuvant chemotherapy in breast cancer. Br J Cancer 1997; 76: 537-540
52. Foekens JA, Look MP, Peters HA. Urokinase-type plasminogen activator and its inhibitor PAI-1: Predictors of poor response to tamoxifen therapy in recurrent breast cancer. J Natl Cancer Inst 1995; 87: 751-756
53. Schmitt M, Wilhelm OG, Reuning U, Krüger A, Harbeck N, Lengyel E, Graeff H, Gänsbacher B, Kessler H, Bürgle M, Stürzebecher J, Sperl S, Magdolen V. The urokinase plasminogen activator system as a novel target for tumour therapy. Fibrinolysis & Proteolysis 2000; 14: 114-132
54. Nozaki S, Endo Y, Nakahara H, Yoshizawa K, Ohara T, Yamamoto E. Targeting urokinase-type plasminogen activator and its receptor fpr cancer therapy. Anti-Cancer Drugs 2006; 17: 1109-1117
55. Pulukuri SM, Gondi CS, Lakka SS, Jutla A, Estes N, Gujrati M et al. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo. J Biol Chem 2005; 280: 36529-36540
56. Berkenblit A, Matulonis UA, Kroener JF, Dezube BJ, Lam GN Cuasay LC et al. Å6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynaecologic cancer: a phase I trial. Gynecol Oncol 2005; 99: 50-57
57. Brooks TD, Wang SW, Brünner N, Charlton PA. XR5967, a novel modulator of plasminogen activatot inhibitor-1 activity suppresses tumor cell invasion and angiogenesis in vitro. Anticancer Drugs 2004; 15: 37-44
58. AGO 2006 guidelines for treatment of early and advanced breast cancer: www.ago-online.de
59. Goldhirsch A, Glick JH, Gelber RD et al. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Annals of Oncology 2005; 16: 1569-1583
60. van 't Veer L, Dai H, van de Vijver MJ et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 530-536
61. Foekens JA, Atkins D, Zhang Y et al. Multicenter validation of a gene expression based prognostic signature in lymph node-negative primary breast cancer. J Clin Oncol 2006; 24: 1665-1671
62. Paik S, Shak S, Tang G et al. A Multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. NEJM; 2004; 351: 2817-2826
63. Olivotto IA, Bajdik CD, Ravdin PM, Speers CH, Goldman AJ, Norris BD, Davis GJ, Chia SK, Gelmon KA. Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol 2005; 23 (12): 2716-2725